

CURRICULUM VITAE

NAME: Richard M. Novak, M.D.

BUSINESS ADDRESS: University of Illinois
Section of Infectious Diseases
808 S. Wood St.
Rm. 874, M/C 735
Chicago, IL 60612

DATE OF BIRTH: January 20, 1954

EDUCATION:

1976	B.A. Grinnell College
1976-77	Graduate study, Genetics, University of Illinois, Champaign
1981	M.D. Rush Medical College

POSTDOCTORAL TRAINING

1981-84	Internship and Residency, Internal Medicine, University of Illinois Medical Center, Chicago
---------	---

1986-89	Fellow, Infectious Diseases University of Illinois and West Side Veteran's Medical Centers, Chicago
---------	---

LICENSURE:

1982	Illinois License Registration No. 036064936 DEA Number AN2367630
------	---

1984	Diplomate, American Board of Internal Medicine
------	--

1988	Infectious Diseases Boards Certification
------	--

HOSPITAL APPOINTMENTS:

1981-84	Assistant in Medicine, University of Illinois Hospital
---------	--

1984-89	Instructor in Medicine, University of Illinois Hospital and Clinics, West Side Veteran's Hospital, Chicago
---------	--

1989-95	Assistant Professor of Medicine, University of Illinois Hospitals and Clinics, West Side Veteran's Hospital, Chicago
---------	--

1995-2003	Associate Professor of Medicine, University of Illinois Hospitals and Clinics, West Side Veteran's Hospital, Chicago
-----------	--

2003-present:	Professor of Medicine, University of Illinois Hospitals and Clinics, West Side Veteran's Hospital, Chicago
---------------	--

2012-present:	Interim Section Chief, Infectious Diseases, University of Illinois Hospitals and Clinics, West Side Veteran's Hospital, Chicago
---------------	---

1989-1999	Director, Infectious Diseases Clinic, Univ. of Illinois Hospitals and Clinics
-----------	---

1992-present:	Director, UIC HIV Community Clinic Network: network of 7 community based, Ryan White HIV primary care clinics throughout Chicago
---------------	--

2005-present:	Vice President, Board of Directors, AID Village Clinics, Kenya A rural Kenyan health care facility operated by a charitable organization. Travel to Kenya to provide training, programmatic recommendations and perform patient care,
---------------	--

**ACADEMIC
APPOINTMENTS**

1976-77 Teaching Assistant, Biology, University of Illinois,
Champaign
1984-89 Instructor in Medicine, University of Illinois, Chicago
Responsibilities included supervision of patient care by housestaff in
the emergency department and clinics; ward and consulting
attending in general internal medicine and Infectious Diseases;
classroom lectures; medical student advisor
1989-95 Assistant Professor of Medicine, University of Illinois, Chicago:
Responsibilities include supervision of patient care by housestaff on
general medicine wards; Director of Infectious Diseases Clinic,
classroom lectures to medical students, consulting attending in
Infectious Diseases, and basic and clinical research
1990-
present Associate Member, Graduate College
1995-2003 Associate Professor of Medicine, University of Illinois, Chicago
2003-
present Full Professor of Medicine, University of Illinois
2012-
present Interim Section Chief, Infectious Diseases, University of Illinois

AWARDS AND HONORS:

1978 Student Research Grant, Foundation of the March of Dimes
1989 Research Award, Chicago Area Infectious Diseases
Society
1998-
present Listing in "Best Doctors In America"
2000 UIC President's Distinguished Speaker List
2010 Nominee, Charles E. Shepard Science Award, CDC
2010, 11 Teaching Excellence Award by UIC Housestaff
2011, 12 Nominee, Hero's Award, American Red Cross
2012 Castle Connolly Top Doctor

COMMITTEE ASSIGNMENTS:

1982-83 Secretary/Treasurer, House Staff Association, U. of Illinois
1984-86 Student Advancement Committee, second year class subcommittee
1986-94: Student Progress Subcommittee
1989-94 Hospital AIDS Advisory Committee
1989-94 University AIDS Advisory Committee
1989-90 Chicago AIDS Advisory Council, Finance Subcommittee
1991-96 Chicago HIV Primary Care Consortium; Chairman, Clinical Care
Subcommittee
1995-2004 Chair, CPCRA Immunology Working Group
2000-2007 Co-Chair, CPCRA 058: FIRST Study (NIH Community Program for
Clinical Research on AIDS)
2002-2005 Co-Chair, CPCRA Virology-Immunology Working Group
2006-2009 HVTN Scientific Steering committee
2006-2009 HVTN Conflict of Interest Committee
2006-
present HVTN Protocol Committee
2007-
present HVTN IDU Working Group
2007-
present HVTN High Risk Women's Working Group
2005-
present Vice President, Board of Directors, AID Village Clinics, Kenya

MEMBERSHIP IN PROFESSIONAL SOCIETIES:

1988-present: American Society for Microbiology
 1988-present: American Association for the Advancement of Science
 1991-present: International AIDS Society
 1992-present: Member, Infectious Disease Society of America
 1996-present: Illinois State Medical Society

GRANT SUPPORT:

Role	Agency	Title of Proposal	Amount Funded	Funding Period
P.I.	Chicago DPH Ryan White	Part A HIV Primary Care	21,125,467	6/1/91-2/28/13
P.I.	Westat/NIAID	DATRI Protocols	90,648	2/1/92-9/26/96
Co-I	NIAID	HIV Antiviral Phospholipids	456,434	12/1/92-9/30/97
P.I.	AIDS Foundation of Chicago (AFC)	HIV Outreach workers	50,202	7/1/93-5/31/95
P.I.	Upjohn	U90157S Rx of HIV Ds/0021	83,905	7/1/94-6/30/98
P.I.	Upjohn	U90157S Rx of HIV Ds/0017	53,294	7/1/94-6/30/96
P.I.	Pharmacia	Rx of MAC Ds in HIV pts	8,480	9/1/94-8/31/95
P.I.	CDPH/Ryan White Title I	Operating support	18,000	11/1/94-5/31/95
P.I.	AFC	HIV Nursing and Outreach	1,097,434	4/1/96-3/31/2007
P.I.	Abt Associates/NIAID	HIV Vaccine Trials	3,150,937	8/1/94-9/30/2000
P.I.	Abbott Labs	HIV1/2 Combo ELISA	25,000	9/1/95-3/31/96
P.I.	Bristol-Myers-Squibb	D4T/3TC clinical trial	43,600	2/1/96-1/31/97
P.I.	Immunex Corp.	GMCSF clinical trial in HIV	85,000	10/1/98-9/30/01
P.I.	VaxGen Corp.	Phase III HIV Vaccine trial	809,448	11/24/98-6/30/02
P.I.	CDC	HIV Vaccine-Related Studies	1,902,325	5/24/00-9/29/03
P.I.	Roche Pharmaceuticals	Fortovase in Women	26,000	9/01/00-8/31/01
P.I.	Pharmacia/Upjohn	Delaverdine 0073	40,000	7/24/98-12/31/99
P.I.	Merck Pharmaceuticals	CRX 497	30,000	6/1/01-12/31/01
P.I.	Boehringer-Ingelheim	1182.6	41,000	8/1/01-12/01/01
Co-I	UO1 AI-48021-01	NIAID: HVTN	87,000	6/1/00-9/30/02
Co-PI	HRSA	Ryan White Title III	675,000	3/1/01-2/29/04
P.I.	NICHD	RO1: HIV Mucosal Immunity	1,098,000	5/1/01-4/30/07
P.I.	DHHS: AHRQ	R18 HS011800-01: HIV Treatment Error Reduction Using a Genotype Database	616,229	10/1/01-9/30/03
P.I.	Norzyme, Inc.	Measurement of PIs in pt serum	27,000	9/1/02-6/01/03
P.I.	NIAID/St. Louis U.	Herpavac Phase III Vaccine	1,900,000	11/1/03-10/31/08
P.I.	Merck	Phase I Trivalent Adenovirus Type 5 HIV-1 Gag/pol/nef Vaccine Prime Boost	213,620	12/1/03-11/30/07
P.I.	HVTN (NIAID)	HIV Vaccine Trials Network Step Study	1,391,328	10/1/04-12/31/09
P.I.	Wyeth	Multivalent HIV Therapeutic	77,100	12/01/04-3/01/07
Co-I	NIAID (subcontract)	CPCRA	21,000	04/1/04-03/31/07
P.I.	HVTN (NIAID)	HIV Vaccine Trials Network Core	7,500,000	01/1/07-12/31/14
Co-PI	NIAID	Pathogenesis of HIV in Women	598,470	09/01/09-8/31/14
Co-investigator, NIAID	Chicago D-CFAR Co-Director, Clinical Core	Chicago D-CFAR Co-Director, Clinical Core	69,595	06/01/09-5/31/14
Site P.I.	CDC/Cerner Corp	HIV Outpatient Study	117,000/yr	06/01/99-5/31/13

Clinical studies completed:

1. Recombinant human erythropoietin in patients on AZT with anemia
2. Daptomycin vs. conventional therapy for the treatment of Gram positive bacteremia
3. Efficacy of a monoclonal antibody, T88A, directed against endotoxin in the treatment of Gram negative sepsis
4. Immunoglobulin light chains as a surrogate marker of HIV disease
5. ACTG 176: Comparative Trial of BV-ARA-U vs. Acyclovir in the treatment of Herpes Zoster in Persons with HIV Infection.
6. Comparison of polyclonal p24 antigen assay and monoclonal p24 antigen assays for use in HIV culture confirmation
7. DATRI 003: Effect of Antiviral therapy on Viral Load in HIV-infected Persons
8. DATRI 004: Treatment of HIV Wasting Syndrome with megesterol acetate and/or dronabinol
9. DATRI 002: Treatment of Primary HIV infection

10. Comparative trial of Clarithromycin/EMB vs. Clarithromycin/EMB/Rifabutin in treatment of Disseminated MAC in pts with AIDS
11. Comparative trial of AZT/3TC vs. D4T/3TC for the treatment of HIV infection in persons with prior AZT experience.
12. DATRI 020: Effect of Acyclovir treatment of HSV on peripheral blood HIV viral load
13. Phase II/III Trials of U90152S, a non-nucleoside RT inhibitor in HIV infection
14. CPCRA Nutrition Study
15. HIVNET VPS1: HIV Vaccine Preparedness study
16. HIVNET 014: Phase II trial of ALVAC/gp120 for prevention of HIV in high risk persons
17. HIVNET VPS2: HIV Vaccine Preparedness study
18. MAK 195F for treatment of Sepsis syndrome with hyperinflammatory response
19. CPCRA: Nelfinavir vs. Ritonavir for the treatment of HIV disease in pts with CD4 <100
20. CPCRA: Bis-pom PMEA (Adefovir dipivoxil) for the treatment of HIV disease in pts with CD4 <100
21. Pharmacia/Upjohn 0073: Delavirdine as part of combination therapy for HIV disease.
22. CPCRA CR-MAC study: Withdrawal of MAC prophylaxis in HIV patients on HAART
23. CPCRA: IL-2 Therapy in HIV patients with early disease.
24. VaxGen 004 Phase III HIV Preventive Vaccine Trial
25. Merck: Concert Study: IDV/RTV vs NFV as part of HAART therapy in patients failing NNRTI containing first line HAART
26. CDC Project Vision: HIV Preventive Vaccine Research as part of the VaxGen 004 Trial
27. Norzyme: Therapeutic Drug Monitoring as a measure of Antiretroviral adherence using the LevoprinZG assay.
28. Agouron: Pharmacokinetics of Nelfinavir 625mg formulation in HIV patients on Nelfinavir
29. CPCRA 058: FIRST Study (Study Co chair)
30. CPCRA 065: SMART Study
31. Merck 016: Phase I Dose-ranging Study of Merck Trivalent Adenovirus Type 5 HIV-1 Gag/pol/nef
32. Vaccine Prime Boost Regimen in Healthy Adults
33. Merck 520-026: A Phase 1 Dose Ranging Study of the Safety, Tolerability, and Immunogenicity of a 3-Dose
34. Regimen of the MRKAd5 HIV-1 Trigene and the MRKAd6 HIV-1 Trigene Vaccines Alone and in Combination in
35. Healthy Adults
36. Merck V520-027: A Phase IIa Dose-Refinement Study of the Safety and Immunogenicity
37. of a 3-Dose Regimen of the Merck Adenovirus Serotype 5 HIV-1 gag/pol/nef Vaccine in Healthy Adults
38. A Phase IV, Multi-center, Cross-Sectional Study to Evaluate the 150L Substitution among Subjects
39. Experiencing Virologic Failure on a HAART Regimen Containing Atazanavir (ATV). A1424128. Version 2.0
40. Esprit Trial: IL-2 as Adjunctive Therapy for Persons with HIV infection
41. NIAID: A Double-blind, Randomized, Controlled Phase III Study to Assess the Prophylactic Efficacy and Safety of gD-Alum/MPL Vaccine in the Prevention of Genital Herpes Disease in Young Women Who are HSV-1 and-2 Seronegative.
42. Merck V520-023; HVTN 502: A Study to Compare a 3-Dose Treatment with the Merck HIV Vaccine (MRKAd5 HIV-1 gag/pol/nef) to Placebo in Adults at High Risk of HIV Infection
43. Randomized Trial of a Switch to Kaletra Plus Current Dual NRTI Backbone versus Continuation of the Current Regimen in Patients with Poor Immune Responses to HAART Despite Complete Viral Suppression: A Pilot Study
44. A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination with TRUVADA. Protocol No. 021
45. HVTN 905-1: Mucosal immune responses in HVTN 502 Participants
46. HVTN 504: Long term follow up of HVTN 502 participants
47. HVTN: 906: HIV Seroincidence in high risk, HIV seronegative women

Ongoing studies:

1. HVTN 505: Phase 2, randomized, placebo-controlled trial to evaluate the safety and effect on post-HIV acquisition viremia of a multiclade HIV-1 DNA plasmid vaccine followed by a multiclade HIV-1 recombinant adenoviral vector vaccine in HIV-uninfected, adenovirus type 5 neutralizing antibody negative, circumcised men
2. HVTN 085: Phase 1 HIV vaccine trial
3. HVTN 092: Phase 1 HIV Vaccine Trial
4. INSIGHT Network: START Study: Strategic timing of antiretroviral therapy.
5. Merck: V503-003 study. Phase III HPV Vaccine trial

PhD STUDENTS:

Mahmood Ghassemi, 1990-1995

Meghan Jendrysik: 1997-2005

Journal Reviewer:

J. Infectious Diseases

AIDS Research and Human Retroviruses

Clinical Infectious Diseases

Journal of Leukocyte Biology

HIV Medicine

Plos-1

AIDS

Lancet Infectious Diseases

ABSTRACTS:

1. R.M. Novak, D. Ou, R. Sulo, and Y. Chen: Variable response to intravenous gamma globulin in a patient with autoimmune neutropenia, thrombocytopenia and pemphigoid. Presented at the American College of Physicians Associate's Meeting, Chicago, May, 1984.
2. R.M. Novak, T.J. Holzer, and C.R. Libertin: Human neutrophil oxidative response to clinical and laboratory strains of Enterococcus faecalis. Presented at the American Society for Microbiology, May, 1988, Miami, Florida.
3. R.M. Novak, T.J. Holzer and C.R. Libertin: Human neutrophil phagocytic killing of hemolysin producing and non-hemolysin producing Enterococcus faecalis. Clin Res. 36(6): 883A, 1988.
4. R.M. Novak, T.J. Holzer, M.M. Kennedy, C.A. Heynen and G. Dawson: The effect of Interleukin 4 on infection of peripheral blood monocyte-derived macrophages with HIV-1. Presented at the Monocyte, Macrophage and HIV Meeting, San Francisco, November 9-10, 1989.
5. D. K. Wagner, M. Kahn, M. Rubenis and R.M. Novak. Inhibition of murine retrovirus replication by a new aspartic protease inhibitor, MK1. Accepted to 1990 Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, Georgia.
6. D.L. Pitrak, R.M. Novak, M. Rubenis and B.R. Andersen. Elevated plasma fibronectin (FN) levels in Human Immunodeficiency Virus infection: inhibition of polymorphonuclear leukocyte (PMNL) function. Accepted at the 1990 Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, Georgia.
7. R.M. Novak, S.S. Bassi, J.E. Hopper, D.L. Pitrak, M.M. Al-Sayyad, G.F. Agringo. Urinary immunoglobulin light chain excretion as a marker of HIV disease progression. Sixth International AIDS Conference, Florence, Italy, June, 1991.
8. R.M. Novak, K. Keyer, A.D. Kinghorn, J.M. Pezzuto. The antiviral activity of the plant extract Fagaronine Hydrochloride, a reverse transcriptase inhibitor in HIV-infected peripheral blood mononuclear cells and T cell lines. Sixth International AIDS Conference, Florence, Italy, June, 1991.
9. S.S. Bassi, R.M. Novak, D.L. Pitrak, A.K. Pau and M.M. Al-Sayyad. Efficacy of aerosolized pentamidine and cotrimoxazole in the prophylaxis of Pneumocystis carinii (PCP) and concurrent incidence of bacterial pneumonias in HIV disease. Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, October, 1991.

10. S. Erdman, K.A. Rodvold, J. Sanchez, S. Antosiak, M. Cwik and R. Novak. Serum protein binding of daptomycin in patients with endocarditis and bacteremia. Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, October, 1991.
11. H.F. Chambers, B. Lee, R.M. Novak, K.A. Rodvold, G. Kaatz, M. Rybak, R. McCloskey, J. Hernandez, M. Zeckel and the daptomycin study group. Daptomycin versus conventional therapy in the treatment of Endocarditis (E) and bacteremia(B). Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, October, 1991.
12. M. Ghassemi, M.V. Reddy, P.R.J. Gangadarum, and R.M. Novak. Effect of IL-2 on intracellular multiplication of *Mycobacterium avium* complex in U937 and U1 cells. Seventh International Conference on AIDS, Amsterdam, Holland, July, 1992
13. T. Holzer, C. Heynen, R. Novak, D. Pitrak. Flow cytometric quantitation of HIV-1 p24 positive CD4 cells. Seventh International Conference on AIDS, Amsterdam, Holland, July, 1992
14. P.L. DeMarais, D.L. Pitrak, P.M. Bak, R.M. Novak, C.A. Heynen, P.J. Maney, and T.J. Holzer. Altered expression of neutrophil (PMNL) surface markers in AIDS. Seventh International Conference on AIDS, Amsterdam, Holland, July, 1992.
15. R.M. Novak and K.A. Keyer. Simple and rapid syncytial cell assay method for screening antiretroviral compounds. Accepted to the Seventh International Conference on AIDS, Amsterdam, Holland, July, 1992.
16. C. Pidgeon, R.J. Markovich, R.M. Novak, M.D. Liu, T.J. Holzer and K.A. Keyer. Synthetic Phospholipids with HIV-Antiviral Activity. Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, October, 1992.
17. M. Ghassemi, M.V. Reddy, P.R.J. Gangadharum, B.R. Andersen and R.M. Novak. Suppression of proliferation by *Mycobacterium avium* complex in HIV-infected and normal healthy controls. Amer.Soc. of Microbiol., Atlanta, GA, 1993.
18. X. Qiu, R.M. Novak and C. Pidgeon. Anti-HIV active Phospholipids: NMR studies of sonicated lipid dispersions. Amer. Assn. Pharmaceutical Scientists, 1993.
19. T.J. Holzer, R.M. Novak and C. Pidgeon. Synthetic Phospholipids inhibit HIV-1 expression in monocyte-derived macrophages. Eighth International Conference on AIDS, Berlin, Germany, 1993.
20. T.P. Kanyok, R.M. Novak and L.H. Danziger. Preliminary results of a randomized, blinded study of paromomycin vs. placebo for the treatment of *Cryptosporidium* diarrhea in AIDS patients. Eighth International Conference on AIDS, Berlin, Germany, 1993.
21. S. McCallister, R.M. Novak, H. Kotler, D.M. Celig, J.M. Stevens and W.M. Janda. Microbiology, radiology and symptoms of sinusitis in HIV-infected persons. Eighth International Conference on AIDS, Berlin, Germany, 1993.
22. T.J. Holzer, C.A. Heynen, R.M. Novak, D.L. Pitrak and G.J. Dawson. Frequency of cells positive for HIV-1 p24 antigen assessed by flow cytometry. Presented at the Workshop on viral quantitation in HIV infection, Paris, France, 1993.

23. C. Pidgeon, R. Markovich, M.D. Liu, R.M. Novak, K. Keyer, T.J. Holzer and S. Cai. Synthesis and antiviral activity of Anti-HIV active phospholipids. American Chemical Society, Chicago, 1993.
24. D.K. Wagner, L.A. Gallenberg, R.M. Novak, M.D. Liu and C. Pidgeon. Inhibition of Murine Retrovirus Replication by HAC phospholipids. Infectious Diseases Society of America, New Orleans, LA, 1993.
25. M. Ghassemi, B.R. Andersen, M.V. Reddy, P.R.J. Gangadharum and R.M. Novak. Interaction Between Human Immunodeficiency Virus and Mycobacterium avium complex in monocytoid cells results in reciprocal enhancement. The First National Conference on Human Retroviruses and Related Infections. Washington, D.C., December, 1993.
26. K. Mullane, D. Pitrak, M. Bilek, R. Novak, R Allen and P Stevens. In vivo neutrophil activation and burnout in HIV infection. Am. Fed. Clinical Res., Baltimore, MD, April, 1994.
27. E.M. Martin, D.L. Pitrak, R.F. Farinpour, R.M. Novak, K.J. Pursell, K.M. Mullane, M.E. Menken and T.E. Harris. Delayed recognition, memory span in HIV-1 infection. International Neuropsychological Society, February, 1995.
28. M. Ghassemi, F.K. Asadi, G.T. Spear, B.R. Andersen and R.M. Novak. Mycobacterium avium complex activates transcription-directed by the Long Terminal Repeat of HIV-1. 2nd National Conf. on Human Retroviruses and Related Infections, Washington, January, 1995.
29. R.M. Novak, D. Szymanski and C. Pidgeon. HIV-antiviral Phospholipid AC2 alters HIV binding and intracellular uptake of AZT in PBMC. 2nd National Conf. on Human Retroviruses and Related Infections, Washington, January, 1995.
30. E.M. Martin, K.M. Mullane, T.E. Harris, D.L. Pitrak, K.J. Pursell, R.M. novak, R.F. Farinpour, M.E. Menken. Self-reported depression and HIV-1 disease severity: gender differences. HIV Infection in Women Conference, February, 1995.
31. R.M. Novak, J. Colombo, M. Linares-Diaz and L. Moreira. Comparison of AZT/3TC vs. D4T/3TC for the treatment of HIV in persons with CD4 counts <300 and prior AZT experience. XI Int'l Conf. on AIDS, Vancouver, Canada, July, 1996.
32. R.M. Novak, D. Engman and M. Ghassemi. Effect of *Trypanosoma cruzi* Infection on Activation of HIV-1 in U1 Cells. 4th National Conf. on Human Retroviruses and Related Infections, Washington, DC, January, 1997:86 (abstract no.120).
33. M. Ghassemi, R.M. Novak, D.E. Schraufnagel and T.M. Folks. Mycobacterium tuberculosis-infected human alveolar macrophages mediate the activation of HIV-1 in U1 and ACH-2 cells. ASM Conference on Tuberculosis: Past, Present, and Future. Copper Mountain, CO. 1997.
34. E.M. Martin, D.L. Pitrak, K.M. Mullane, K.J. Pursell, R.M. Novak, V.L. Carson, J. Arruda, J. Somerville and R.A. Stern. Reaction time performance of HIV-seropositive women. National Conf. Women HIV, San Diego, CA, May, 1997.
35. R.M. Novak, M.L. Sirdar, L. Moreira, M. Ghassemi. Lymphoproliferative Responses to Mitogens and Prepared antigens of M. avium Complex in patients with HIV Infection. Infectious Disease Society of America Annual Meeting, San Francisco, CA, September, 1997.

36. D. Mildvan, M. Fischl, T. Creagh, S. Grossberg, R. Novak, P. Witt, S. Machado, M. Mahmud, A. Marshak and D.D. Richman. The role of immune activation markers in antiretroviral naive patients with advanced HIV disease. Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, October, 1997.
37. D.J. McKirnan, R.M. Novak, C. Smith, D. Metzger, P. Brown-Peterside, K. Mayer, M. Marmor. Feasibility of Post-Exposure Prevention Research among women at HIV risk though heterosexual exposure. 12th World AIDS Conference, Geneva, Switzerland, July, 1998.
38. R.M. Novak, M. Ghassemi, N. Plotnikoff. Methionine enkephalin, a new cytokine inhibits HIV replication in PBMC. 12th World AIDS Conference, Geneva, Switzerland, July, 1998;12:1096-7 (abstract no. 60525).
39. CA Smith, RM Novak, D Pollins, BA Jacob, G Davis-Miller, P Newman, F Freeman. Secondary traumatic stress syndrome: understandings and coping mechanisms learned during HIV prevention research at the University of Illinois at Chicago. 12th World AIDS Conference, Geneva, Switzerland, July, 1998;12:498 (abstract no. 24302).
40. G. Skowron, G. Leoung, D. Johnson, A. Fisher, R. Hewitt, B. Bernstein, C. Achenbach, R. Novak, A. Stein and C. Giffen. The Nevirapine/Nelfinavir Database: Viral load and CD4+ cell count responses in 118 patients in 9 US clinical practices. Infectious Disease Society of America Annual Meeting, Denver CO, November, 1998.
41. S.K. Chuck, C.A. Lesch, M. Diaz-Linares, J. Sanchez-Colombo, R.M. Novak and K.A. Rodvold. Protease Inhibitors (PI) in clinical practice at an inner-city HIV clinic. Infectious Disease Society of America Annual Meeting, Denver CO, November, 1998.
42. D. Slobodkin, J.L. Kitlas, Luiz Moreira and R. Novak. Seroprevalence of syphilis in an inner-city emergency room. American Public Health Association Convention, Washington DC, November, 1998.
43. D. Slobodkin, J.L. Kitlas, Luiz Moreira and R. Novak. Seroincidence/Seroprevalence of HIV in an inner-city emergency room. American Public Health Association Convention, Washington DC, November, 1998
44. J Bolanos, D Pitrak, R Novak R Hershow. Immunologic Responses in Patients with Virologic Response to Antiretroviral Therapy Is Associated with a Decreased Rate of Ex Vivo Apoptosis. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, January, 2000.
45. R.M. Novak, A.V. Munsiff, M. Diaz-Linares, N. D'Alfonso-Laghi, R. Smith, P. Kokoski. Effect of Change from TID to BID Nelfinavir on Adherence and outcome in HIV management. 2nd Annual Conf. On Antiretroviral Resistance, Frankfurt, Germany, February, 2000.
46. R.M. Novak, A.V. Munsiff, J. Post, D. Melton, M. Diaz-Linares, J. Bolanos, N. D'Alfonso-Laghi, R. Smith, P. Kokoski. Effect of Change from TID to BID Nelfinavir (NFV) on Viral Load, CD4 Count and Adherence. XIII Int'l AIDS Conference, Durban South Africa, July, 2000.
47. R. M. Novak, L. Baum, P. Nog, G. Spear, G. Tim, C. Hanson. Absence of antibodies with Neutralizing or Antibody-Dependent Cellular Cytotoxic activity in vaginal secretions after parenteral vaccination with ALVAC vCP205 and rgp120 in high risk women in the U.S. XIII Int'l AIDS Conference, Durban South Africa, July, 2000.

48. M. Diaz-Linares, M. M. Neuhauser, D. T. Bearden, A. Wendrow, A. J. Hoffman, and R. M. Novak. Efficacy and Safety of Indinavir and Ritonavir Containing HAART Regimens in an Urban Clinic. 38th Annual Inf. Dis. Society of America Meeting, San Francisco, CA, September, 2000.
49. R. M. Novak, L.L. Baum, J. Bolanos, M. Diaz-Linares, M. Ghassemi, P. Nag, B.K. Patterson, D.L. Pitrak, H. Sagha, D. Schiappa. Effect of GMCSF on Viral Load, CD4 count and Lymphocyte Function in HIV Patients Receiving HAART. Ist IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina, July, 2001.
50. R. Novak, P. Graham, P. Brown-Peterside, B. Koblin, M. Lally, K. Mayer and the VaxGen 004 Study Team. Comparison of Men and Women Participating in a Phase III HIV Vaccine Efficacy Trial of AIDS VAX[®] B/B in the U.S. AIDS Vaccine 2001, Philadelphia, PA, September, 2001.
51. R.M. Novak, K. Greenberg, M. Diaz-Linares, M. Schutz, W.C. Woodward, J.R. Kostman, P. Bensen, D.S. Rubin, S. Segal-Maurer. Retrospective observational study of combination delavirdine and lopinavir/ritonavir as part of salvage therapy in highly treatment-experienced patients. Abst. TuPeB4486. 14th Int'l AIDS Conf., Barcelona, July, 2002.
52. Z. Gan, J. Ma, J. Wallman, R.M. Novak, M. Teodorescu. Rapid fluorometric method for the measurement of HIV protease inhibitor levels in patient serum. Abst. WePeB5871. 14th Int'l AIDS Conf., Barcelona, July, 2002.
53. R.M. Novak, Z. Gan, J. Ma, J. Wallman, M. Teodorescu. Functional measurement of HIV protease inhibitor levels in patient serum by a rapid fluorometric method. Abst. WePeB5872. 14th Int'l AIDS Conf., Barcelona, July, 2002.
54. M.L. Ackers, S. Buchbinder, D. McKirnan, K.H. Mayer, R. Novak, C. Harro, V. Popovic, W. Heyward, M. Para. J. Fuchs, S. Tabet, Vax004 Study Team. Post-exposure prophylaxis among HIV-uninfected participant in a phase III HIV vaccine efficacy trial. Abst. WePpD2105. 14th Int'l AIDS Conf., Barcelona, July, 2002.
55. R.D. MacArthur, L. Chen, G. Peng, R.M. Novak, M. van den Berg-Wolf, M. Kozal, C.L. Besch, T. Yurik. Efficacy and safety of ABC+3TC versus DDI+D4T when combined with an NNRTI, PI or both in AR-naive persons on their first HAART regimen: the NRTI substudy of the CPCRA 058 FIRST study. The 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, France, July, 2003, Abstract no. 555.
56. S.P. Buchbinder, S.L. Wheeler¹, E. Vittinghoff², K.H. Mayer³, C.L. Celum⁴, R. Novak, D. McKirnan⁶, M.F. Para⁷, M. Gurwith⁸, M. Longhi⁸, M. Ackers. Timing and factors associated with antiretroviral use among participants who became HIV infected in a Phase III HIV vaccine trial. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February, 2004.
57. P. Patel, R. M. Novak, T. Tong, P. Behari, A. C. Moorman, F. Palella, S. D. Holmberg. Incidence of non-AIDS defining malignancies in the HIV Outpatient Study (HOPS). 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February, 2004.
58. B.K. Patterson¹, G. Spear², A. Landay², R.M. Novak³ Effects of Pre- and Post-Trichomonas Therapy CVL Supernatants Applied to Cervical Explant Tissues on the Susceptibility to HIV-1 Infection. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February, 2004.

59. M.A. Jendrysik, A.L. Landay and R.M. Novak. A Natural Inhibitor of HIV-DC-SIGN Interactions in the Female Genital Tract: Inhibition is HIV Strain-Dependent Keystone Symposium on Molecular Mechanisms of HIV Pathogenesis. Whistler, B.C., Canada, April, 2004.
60. Jenney Kim, R.M. Novak, A. Landay, P. J. Graham, L. L. Baum . ADCC is present in the cervical lavage fluid of HIV exposed seronegative women. FASEB Experimental Biology 2004 Meeting, Washington, D.C., April, 2004.
61. R.M. Novak, M. Teodorescu, R.D. MacArthur, C.B. Hare, M.A. Fischl, F. Palella, W. C. Hanly, J. Ma, J. Sychra, Z. Gan. Results from a Rapid, Solid Phase HIV-1 Protease Inhibitor (PI) Quantitation Assay Correlate Better with Viral Load (VL) and CD4 Responses than does Self-Reported Adherence. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, October, 2004.
62. S Buchbinder, S L Wheeler, E Vittinghoff, K H Mayer, C Celum, R Novak, D McKirnan⁷, M F Para, M Gurwith, M Longhi, and M Ackers. Timing and Factors Associated with Antiretroviral Use among Participants Who Became HIV Infected in a Phase 3 HIV Vaccine Trial. 14th Conference on Retroviruses and Opportunistic Infections, Denver. CO, February, 2005.
63. M.J. Kozal, K. Huppler Hullsiek, R.D. MacArthur, G. Peng, Y. Xiang, J.D. Baxter, M. Van den Berg-Wolf, J.P. Uy, E.E. Telzak, and R.M. Novak . Initial Virologic Failure with HIV Drug Resistance and Impact of Resistance on Disease Progression and Death for Patients Beginning PI, NNRTI or PI+NNRTI Based Strategies: The FIRST Study. XV Intl IV drug resistance workshop, Sitges, Spain, 2006.
64. R.M. Novak, B.A. Donoval, P.J. Graham, L.A. Boksa, G. Spear, R.C. Hershow, H.Y. Chen and A. Landay. Prevalence of Lactoferrin (Lf) and secretory leukocyte protease inhibitor (SLPI) in the genital tract and the influence of concurrent vaginosis in women at both low and high risk for HIV infection. XVI International AIDS Conf., Toronto, CA, August, 2006.
65. J.A. Schneider, B. Parekh, M. Ackers, H.Y. Chen, P.J. Graham, M. Gurwith, R.C. Hershow, K. Mayer, R.M. Novak. Mucosal HIV Binding Antibody (BAB) and Neutralizing Activity (NA) in Response to a Bivalent Glycoprotein (gp) 120 Preventive Vaccine in a High-Risk HIV Uninfected Cohort of Women from Chicago Participating in the VaxGen VAX004 Trial. XVI International AIDS Conf., Toronto, CA, August, 2006.
66. R.D. MacArthur, R.M. Novak, G. Peng, L. Chen, Y. Xiang, K. Huppler Hullsiek, M.J. Kozal, M. van den Berg-Wolf, C. Henely, B. Schmetter, M. Dehlinger for the CPCRA 058 Study Team and the Terry Bein Community Programs for Clinical Research on AIDS. Long-Term Clinical and Immunologic Outcomes Are Similar in HIV-Infected Persons Randomized to NNRTI versus PI versus NNRTI+PI-based Antiretroviral Regimens as Initial Therapy: Results of the CPCRA 058 FIRST Study. XVI International AIDS Conf., Toronto, CA, August, 2006.
67. M. van den Berg-Wolf, G. Peng, Y. Xiang, K. Huppler Hullsiek, L. Chen, R.D. MacArthur, R.M. Novak, M. Kozal, B. Schmetter, C. Henely, M. Dehlinger for the CPCRA 058 Study Team and the Terry Bein Community Programs for Clinical Research on AIDS. Long-Term Comparison of Nevirapine Versus Efavirenz When Combined with Other Antiretroviral Drugs in HIV-1 Positive Antiretroviral-Naïve Persons. XVI International AIDS Conf., Toronto, CA, August, 2006.
68. P. Patel, D Hanson, R Novak, A Moorman, T Tong, S Holmberg, J Brooks, P Sullivan, and Adult/Adolescent Spectrum of Disease (ASD) and HIV Outpatient Study (HOPS) Investigators.

Declining Incidence of Cancers among HIV-infected Persons in the United States in the HAART Era. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February, 2007

69. M. Para, J Fuchs, C Celum, R Novak, M Gurwith, K Mayer, A Youngpairoj, M Kalish, W Heneine, and M Ackers. HIV Genotypic Resistance in Seroconverters in the gp120 Vaccine Efficacy Trial. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February, 2007

70. F. Palella, C Armon, J Chmiel, K Buchacz, R Novak, A Moorman, J Brooks, and the HOPS Investigators. Enhanced Survival Associated with Use of HIV Susceptibility Testing among HAART-experienced Patients in the HIV Outpatient Study (HOPS). 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February, 2007.

71. P. Patel, D Hanson, R Novak, A Moorman, T Tong, S Holmberg, P Sullivan and J Brooks,. Incidence of AIDS Defining and Non-AIDS Defining Malignancies among HIV-infected Persons. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February, 2007.

72. F. Priddy, D Wright, J Lalezari, S Santiago, R Novak, S Brown, M Lally, M Marmor, J Kublin, R Leavitt, R Isaacs, D Mehrotra, J Shiver, D Brown, and V520 Protocol 016 Study Group. Safety and Immunogenicity of the MRK Adenovirus Type-5 gag/pol/nef HIV-1 (Trivalent) Vaccine in Healthy Adults. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February, 2007.

73. R. Novak, L. Baum, P. Graham, H. Chen, W. Yang, and B. Parekh. Prevalence and characterization of HIV adaptive immune responses in genital mucosal secretions from a cohort of high heterosexual risk, seronegative women in Chicago. Abstract 360. 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February, 2008

74. F. Palella, R. Baker, J. Chmiel, E. Tedaldi, R. Novak, K. Buchacz, J. Brooks. Higher mortality rates among publicly insured patients and blacks in the HIV Outpatient Study. Abst. 530. 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February, 2008

75. K. Huppler Hullsiek, G. Peng, B. Simen, J. Simons, M. Egholm, R. Novak, R. MacArthur, M. Kozal. Virologic Success of Different Strategies for initial ART regimens is predicted by the type and detection level of minor drug-resistant variant detected by Ultra-Deep sequencing: The CPCRA 058 FIRST Study. Abst. 878. 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February, 2008

76. Frank Palella Jr, C Armon, J Chmiel, K Buchacz, R Novak, J Brooks, and the HOPS Investigators. Clinical and Genotypic Factors Associated with Enhanced Survival among Persistently Viremic Triple ARV Class-experienced Patients in the HIV Outpatient Study. Abst. 660. 16th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada, February, 2009.

77. RM Novak, JT Richardson, K Buchacz, JS Chmiel, M Durham, FJ Palella, A Wendrow, K Wood, B Young, JT Brooks and the HOPS Investigators. Manifestations and Risk Factors for Immune Reconstitution Inflammatory Syndrome (IRIS) in the HIV Outpatient Study (HOPS), 1996-2007. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Capetown, South Africa, July, 2009.

78. D Boulware, K Huppler Hullsiek, C Puronen, A Rupert, J Baker, M French, P Bohjanen, R Novak, J Neaton, Irini Sereti, and the INSIGHT Group. Higher Levels of D-dimer, C-reactive Protein, Hyaluronic Acid, and IL-6 before Initiation of ART Are Associated with AIDS, IRIS, or Death among ART-naive Patients with a Good Virologic Response to Initial ART. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Feb, 2010.

79. CD4 at HAART Initiation Predicts Long Term CD4 Responses and Mortality from AIDS and non-AIDS Causes in the HIV Outpatient Study (HOPS). Frank Palella, C Armon, K Buchacz, B Yangco, J Chmiel, R Novak, K Wood, M Durham, J Brooks, and the HOPS Investigators. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Feb, 2010.
80. Survival after Cancer Diagnosis and Factors Associated with All-Cause Mortality among HIV-infected Persons with Cancer in the HIV Outpatient Study (HOPS) during the HAART Era. P Patel, JT Brooks, C Armon, K Buchacz, JS Chmiel, K Wood, RM Novak and the HOPS Investigators. 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA, Feb, 2011.
81. GBV-C viremia is Associated with HIV-1 Neutralization in the Genital Tract of Highly-Exposed HIV-Seronegative Women. Olamide Jarrett, Jack Stapleton, Linda L. Baum, Alan Landay, Donna Klinzman, and Richard Novak. 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA, Feb, 2011.
82. Premature Age-related changes in monocytes from HIV+ women. G. Martin, M Gouillou¹, A Hearps, C Palmer, T Angelovich, A Cheng, A Jaworowski, R Novak, A. Landay, S. Crowe. 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, Feb, 2012.
83. Risk of common cancers by age 60 for HIV-positive patients in the United States and Canada M.J. Silverberg, B. Lau, Y. Jing, C. Achenbach, K. Althoff, R. Bosch, J.T. Brooks, A. Burchell, H. Crane, G. D'Souza, M.J. Gill, J.J. Goedert, N.A. Hessol, A.C. Justice, R. Hogg, G.D. Kirk, M.M. Kitahata, M.B. Klein, J.N. Martin, W.C. Mathews, R.D. Moore, S. Napravnik, R. Novak, P. Patel, A. Rachlis, B. Rodriguez, T.R. Sterling, J. Willig, R. Dubrow, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. 19th International Conference on AIDS, Washington DC, July, 2011
84. Age at cancer diagnosis in HIV-positive individuals in North America compared to the general U.S. population. M. Shiels, K. Althoff, C. Achenbach, A. Abraham, A. Burchell, A. Cescon, H. Crane, G. D'Souza, M.J. Gill, N. Hessol, A. Justice, G. Kirk, M. Klein, W.C. Mathews, R. Moore, S. Napravnik, R. Novak, B. Rodriguez, J. Schouten, T. Sterling, J. Thorne, J. Willig, M. Silverberg, E. Engels, on behalf of the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. 19th International Conference on AIDS, Washington DC, July, 2011
85. Apoptosis Pathways and Immune Recovery in HIV-1 infected patients before and after HAART. D Pitrak, R Novak, R Estes, J Tschampa, A. Tenorio, A. Landay. Infectious Diseases Society of America Annual Meeting, San Diego, CA, Sept, 2012.

PUBLICATIONS:

1. R.M. Novak and D.C. Robinson: Observations on the reproduction and ecology of the tropical montane toad, Bufo holdridgei Taylor in Costa Rica. Rev. Biol. Trop.,23(2): 213-237, 1975.
2. R.M. Novak, D. Ou, R. Sulo and Y. Chen: Variable response to intravenous gamma globulin in a patient with autoimmune neutropenia, thrombocytopenia and pemphigoid. Southern Medical Journal. 81(5):653-655, 1988.
3. R.M. Novak, B. Duarte and J.B. Leikin: Use of thrombolytic therapy in axillary-subclavian vein thrombosis. Am J. Emergency Med. 6(2):120-123, 1988.

4. R.M. Novak, E. Polisky, W.M. Janda and C.R. Libertin: Osteomyelitis caused by Rhodococcus equi in a renal transplant patient. *Infection*. 16: 56-58, 1988.
5. R.D. Pryka, R.M. Novak, D.K. Wagner and K.A. Rodvold: Clinical Pharmacokinetics of Daptomycin. *DICP, Ann Pharmacotherapy*. 24:255-6, 1990.
6. R.M. Novak, T.J. Holzer, M. M. Kennedy, C.A. Heynen and G. Dawson: The effect of Interleukin 4 (BSF-1) on infection of peripheral blood monocyte-derived macrophages with HIV-1. *AIDS Res. Human Retroviruses*. 6: 973-976, 1990.
7. R.M. Novak, T.J. Holzer and C.R. Libertin. Oxidative response and phagocytic killing of clinical and laboratory strains of Enterococcus faecalis. *Diagnostic Microbiol Inf Dis*. 17: 1-6. 1993.
8. L.H. Danziger, T.P. Kanyok and R.M. Novak. Treatment of cryptosporidial diarrhea in an AIDS patient with paromomycin. *Ann Pharmacotherapy* 27:1460-1462. 1993
9. C. Pidgeon, R.J. Markovich, M.L. Liu, T.J. Holzer, R.M. Novak and K.A. Keyer. Anti-HIV Active Phospholipids: Drugs conjugated to the Glycerobackbone of Phospholipids. *J. Biological Chemistry*, 268: 7773-7778, 1993
10. Ang, G.A.T., Janda, W.M., R.M. Novak and Gerardo, L.: Negative Images of Mycobacteria in the Lymph Node Aspiration Biopsies of a Patient With AIDS. *Diagnostic Cytopathology*, 9: 325-328, 1993.
11. D.L. Pitrak, P.M. Bak, P.L. DeMarais, R.M. Novak and B.R. Andersen.: Depressed Neutrophil Superoxide Production in Human Immunodeficiency Virus Infection. *J. Infect. Dis*. 167: 1406-1410. 1993.
12. T.J. Holzer, C.A. Heynen, R.M. Novak, D.L. Pitrak and G.J. Dawson. Frequency of cells positive for HIV-1 p24 antigen assessed by flow cytometry. *J. AIDS*, 7: S3-S5. 1993.
13. M. Ghassemi, B.R. Andersen, M.V. Reddy, P.R.J. Gangadharum, G. Spear, and R.M. Novak. Interaction Between Human Immunodeficiency Virus and Mycobacterium avium complex in monocytoid cells results in reciprocal enhancement. *J. Infect. Dis.*, 171:68-73. 1995.
14. E.M. Martin, K.M. Mullane, T.E. Harris, D.L. Pitrak, K.J. Pursell, R.M. Novak, R.F. Farinpour and M.E. Menken. Self-reported depression and HIV-1 disease severity: gender differences. *HIV Infect. Women*. Feb 22-24, p.94. 1995.
15. O.J. Cohen, G. Pantaleo, M. Holodniy, S. Schnittman, M. Niu, C. Graziosi, G.N. Pavlakis, J. Lalezari, J.A. Bartlett, R.T. Steigbigel, J. Cohn, R. Novak, D. McMahon and A.S. Fauci. Decreased HIV-1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissue. *Proc. Nat. Acad. Sci.*, 92:6017-6021. 1995.
16. E.M. Martin, D.L. Pitrak, K.M. Mullane, K.J. Pursell, and R.M. Novak, Delayed recognition memory span in HIV-1 infection. *Journal of the International Neuropsychological Society* 1:575-580. 1995.
17. E.M. Martin, D.L. Pitrak, L.C. Robertson, R.M. Novak, K.M. Mullane, and K.J. Pursell. Global-local analysis in HIV-1 infection. *Neuropsychology*, 9:102-109. 1995.
18. N.L. McCain, J.M. Zeller, D.F. Cella, P.A. Urbanski and R.M. Novak. The influence of stress management training in HIV disease. *Nursing Research*, 45: 246-53. 1996.

19. O.J.Cohen, G. Pantaleo, M. Holodniy, C.H. Fox, J.M. Orenstein, S. Schnittman, M. Niu, C. Graziosi, G.N. Pavlakis, J. Lalezari, J.A. Bartlett, R.T. Steigbigel, J. Cohn, R. Novak, D. McMahon and A.S. Fauci. Antiretroviral monotherapy in early stage Human Immunodeficiency Virus Disease has no detectable effect on virus load in peripheral blood and lymph nodes. *J. Infect. Dis.* 173:849-56. 1996.
20. C.A. Gentry, K.A. Rodvold, R.M. Novak, R.C. Hershow and O.J. Naderer. Retrospective evaluation of therapies for *Staphylococcus aureus* endocarditis. *Pharmacotherapy*, 17: 990-7. 1997.
21. J.A. Bartok, E.M. Martin, D.L. Pitrak, R.M. Novak, K.J. Pursell, K.M. Mullane and M. Harrow. Working memory deficits in HIV-seropositive drug users. *J. Int. Neuropsychol. Soc.*, 3: 451-6. 1997.
22. J.G.Timpone, D.J. Wright, N.Li, M.J. Egorin, M.E. Enama, J. Mayers, G. Galetto, and the **DATRI 004 Study Group**. The safety and pharmacokinetics of single agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. *AIDS Research Human Retroviruses*. 13:305-315. 1997.
23. E.M. Martin, D.L. Pitrak, K.J. Pursell, B.R. Andersen, K.M. Mullane and R.M. Novak. Information processing and antiretroviral therapy in HIV-1 infection. *J. Int. Neuropsychol. Soc.*, 4: 329-35. 1998.
24. A.L. Landay, J. Bethel, S.Schnittman for the **DATRI 003 Study Group**. Phenotypic variability of lymphocyte populations in peripheral blood and lymph nodes from HIV-infected individuals and the impact of antiretroviral therapy. *AIDS Research Human Retroviruses*. 14:445-451. 1998.
25. M.T. Niu, J. Bethel, M. Holodniy, H.C. Standiford, S.M. Schnittman and the **DATRI 002 Study Group**. Zidovudine treatment in patients with primary (acute) Human Immunodeficiency Virus Type 1 infection: a randomized, double blinded, placebo-controlled trial. *J. Infect. Dis.*, 178:80-91. 1998.
26. E.M. Martin, D.L. Pitrak, R.M. Novak, K.J. Pursell, and K.M. Mullane. Reaction times are faster in HIV-seropositive patients on antiretroviral therapy: a preliminary report. *J. Clin. Exp. Neuropsychol.* 21:730-735. 1999.
27. M. Ghassemi, B.R. Andersen, K.A. Roebuck, M.F. Rabbi, J.M.D. Plate, and R.M. Novak. *Mycobacterium avium* Complex Activates Nuclear Factor kB via Induction of Inflammatory Cytokines. *Cellular Immunology*, 191:117-123, 1999.
28. M. Ghassemi, F.K. Asadi, B.R. Andersen, and R.M. Novak. *Mycobacterium avium* Induces HIV Upregulation Through Mechanisms Independent of Cytokine Induction. *AIDS Research Human Retroviruses*, 16(5):435-440. 2000
29. R. Farinpour, E.M. Martin, M. Seidenburg, D.L. Pitrak, K.J. Pursell, K.M. Mullane, R.M. Novak, M. Harrow. Verbal working memory in HIV-seropositive drug users. *J. Int. Neuropsychol Soc.* 6(5):548-55. 2000.
30. R.M. Novak, J. Koirala, M.L. Sirdar, N. D' Alfonso-Laghi, L. Moreira, D.L. Pitrak, and M. Ghassemi, Lymphoproliferative Responses to Mitogens and Prepared Antigens of *M. avium* Complex in Patients with HIV Infection. *J. Clin. Immunol.*, 20:62-67.2000.

31. R.D. MacArthur, L. Chen, D.L. Mayers, C.L. Besch, R. Novak, M. van den Berg-Wolf, T. Yurik, G. Peng, B. Schmetter, B. Brizz, D. Abrams. The rationale and design of the CPCRA 058 FIRST (Flexible initial retrovirus suppression therapies) trial. *Controlled Clinical Trials*, 22:176-190. 2001.
32. D.L. Pitrak, J. Bolanos, R.Hershow, R.M. Novak. Discordant CD4 T lymphocyte responses to antiretroviral therapy for HIV infection are associated with ex-vivo rates of apoptosis. *AIDS*, 15(10): 1317-1319. 2001.
33. J.K.Keithley, B. Swanson, J.M. Zeller, B.E. Sha, M. Cohen, R. Hershow and R.Novak. Comparison of standard and immune-enhancing oral formulas in asymptomatic HIV-infected persons: a multicenter randomized controlled clinical trial. *J. Parenteral and Enteral Nutr.*, 26, 6-14.2002.
34. W.M. Janda, P. Tipirneni and R.M. Novak. *Brevibacterium casei* bacteremia and line sepsis in patients with AIDS. *J. Infection*, 46 (1): 61-64.2003.
35. M. Ghassemi, R. M. Novak, M. F. Khalili and J. Zhou Viable *Mycobacterium avium* required for the majority of human immunodeficiency virus-induced upregulation in monocytoïd cells. *Journal of Medical Microbiology*, 52:1–6. 2003.
36. M. P. Pai, C. A. Schriever, M. Diaz-Linares, R. M. Novak, K. A. Rodvold, Sex-Related Differences in the Pharmacokinetics of Once Daily Saquinavir Sof:592-599.2004.
37. M. R. Zariffard, S. Harwani, R. M. Novak, P. J. Graham, J. Xin, and G. T. Spear *Trichomonas vaginalis* infection activates cells through toll-like receptor 4. *Clin. Immunol.*, 111(1):103-7.2004.
38. E. M. Martin, R. M Novak, M. Fendrich, J. Vassileva, R. Gonzalez, S. Grbesic, G. Nunnally, and L. Sworowski. Stroop Performance in Drug Users Classified by HIV and Hepatitis C Virus Serostatus. *Journal of the International Neuropsychological Society*, 10(2):298-300.2004.
39. RD MacArthur, L Chen, G Peng, RM Novak, M van den Berg-Wolf, M Kozal, L Besch, T Yurik, B Schmetter, C Henley, M Dehlinger and the CPCRA 058 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). Efficacy and Safety of Abacavir plus Lamivudine versus Didanosine plus Stavudine when Combined with a Protease Inhibitor, a Non-Nucleoside Reverse Transcriptase Inhibitor or Both in HIV-1 Positive Antiretroviral-Naïve Persons HIV Clinical Trials, Nov-Dec;5(6):361-70. 2004.
40. Richard M. Novak, Li Chen, Rodger D. MacArthur, John Baxter, Kathy Huppler Hullsiek, Grace Peng, Ying Xiang, Christopher Henley, Barry Schmetter, Jonathan Uy, Mary van den Berg-Wolf, Michael Kozal and the CPCRA 058 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). Prevalence of Antiretroviral Drug Resistance Mutations in Chronically HIV-Infected, Treatment Naïve Participants in the CPCRA FIRST Study: Implications for Routine Resistance Screening Prior to Initiating Antiretroviral Therapy. *Clinical Infectious Diseases* 40:468–74. 2005.
41. Bradford N. Bartholow, Susan Buchbinder, Connie Celum, Vamshidar Goli, Beryl Koblin, Michael Para, Michael Marmor, Richard M. Novak, Kenneth Mayer, Catherine Creticos, Patti Orozco-Cronin, Vladimir Popovic, and Timothy D. Mastro for the VISION/VAX004 Study Team HIV Sexual Risk Behavior over 36-Months of Follow-up in the World’s First HIV Vaccine Efficacy Trial. *J Acquir Immune Defic Syndr*; 39:90–101. 2005

42. M. Reza Zariffard, RM Novak, N. Lurain, B.E. Sha, P. Graham and G. T. Spear. Induction of TNF- α Secretion and Expression of Toll-Like Receptors 2 and 4 by Genital tract Secretions from Women with Bacterial Vaginosis. *J. Infect. Dis.*, 191:1913-21. 2005
43. R. Gonzalez, J. Vassileva, A. Bechara, S. Grbesic, L. Sworowski, R.M. Novak, G. Nunnally and E. Martin. The influence of executive functions, sensation seeking, and HIV serostatus on risky sexual practices of substance-dependent individuals. *J. Int. Neuropsychol. Soc.* 11(2):121-131. 2005
44. Meghan A. Jendrysik, Mahmood Ghassemi, Parrie J. Graham, Lucy A. Boksa, Richard M. Novak. Human cervicovaginal lavage fluid contains an inhibitor of HIV binding to dendritic cell-specific intracellular adhesion molecule 3-grabbing nonintegrin. *J. Infect. Dis.* 192:630-9. 2005
45. Michael J. Kozal, Katherine Huppler Hullsiek, Robert Leduc, Richard M Novak, Rodger D MacArthur, Jody Lawrence, and John D Baxter for the Terry Bein Community Programs for Clinical Research on AIDS (CPCRA). Prevalence and Impact of HIV-1 Protease Codon 33 Mutations and Polymorphisms in Treatment-Naïve and Treatment-Experienced Patients Enrolling in Clinical Trials. *Antiviral Ther.* 11(4):457-63. 2006.
46. RD MacArthur, RM Novak, G Peng, L Chen, Y Xiang, K Huppler Hullsiek, MJ Kozal, M van den Berg-Wolf, C Henely, B Schmetter, M Dehlinger for the CPCRA 058 Study Team and the Terry Bein Community Programs for Clinical Research on AIDS (CPCRA) Long-Term Clinical and Immunologic Outcomes Are Similar in HIV-Infected Persons Randomized to NNRTI versus PI versus NNRTI+PI-based Antiretroviral Regimens as Initial Therapy: Results of the CPCRA 058 FIRST Study. *Lancet*, 368 (9553): 2107-9. 2006.
47. JE Cummins Jr., M Denniston, KH Mayer, R Pickard, RM Novak P Graham, M Gurwith, K Orelind, ML Ackers, and CS Dezzutti. Mucosal Innate Immune Factors in Secretions from High Risk Individuals Immunized with a Bivalent gp120 Vaccine. *AIDS Research Human Retroviruses*, 23(5): 748-54. 2007.
48. J Uy, J Brooks, R Baker, M Hoffman, A Moorman, R Novak, and the HOPS Investigators. HIV Genotypic Resistance Testing to Optimize Antiretroviral Prescribing: Is There Room for Improvement? *Antiviral Therapy*, 12:957-962. 2007
49. RM Novak, BA Donoval, PJ Graham, LA Boksa, G Spear, RC Hershow, HY Chen and A Landay. Lactoferrin, Secretory Leukocyte Protease Inhibitor and RANTES (regulated on activation, normal T cell expressed and secreted) in the Genital Tract of Sexually High Risk, HIV-seronegative Women and the effect of coexisting vaginosis. *Clin. Vaccine Immunol.* Sep;14(9):1102-7. 2007.
50. JA Schneider, SA Alam, M Ackers, B Parekh, HY Chen, P Graham, M Gurwith, K Mayer, RM Novak. Mucosal HIV Binding Antibody and Neutralizing Activity among High-Risk HIV-Uninfected Female HIV Vaccine Trial Participants, *J. Infect. Dis.*, 196:1637-44. 2007.
51. MJ Kozal, K Huppler Hullsiek, RD MacArthur, M van den Berg-Wolf, G Peng, Y Xiang, JD Baxter, J Uy, EE Telzak and RM Novak for the Terry Bein Community Programs for Clinical Research on AIDS (CPCRA). The Incidence of HIV Drug Resistance and Its Impact on Progression of HIV Disease Among Antiretroviral Naïve Participants Started on Three Different Antiretroviral Therapy Strategies. *HIV Clin Trials*, 27. 8 (6): 357-370. 2007.
52. D Mares, JA Simoes, RM Novak and GT Spear: TLR2-Mediated Cell Stimulation in Bacterial Vaginosis. *Journal of Reproductive Immunology*, 77(1):91-99. 2008

53. FH Priddy, D Brown, J Kublin, K Monahan, DP Wright, J Lalezari, S Santiago, M Marmor, M Lally, RM Novak, J Brown, P Kulkarni, SA Dubey, LS Kierstead, DR Casimiro, R Mogg, MJ DiNubile, JW Shiver, RY Leavitt, MN Robertson, DV Mehrotra, E Quirk For the Merck V520-016 Study Group. Safety and Immunogenicity of a Replication-Incompetent Adenovirus Type-5 HIV-1 Clade B gag/pol/nef Vaccine in Healthy Adults. *Clin Infect Dis.* Jun 1;46(11):1769-81. 2008
54. P Patel, DL Hanson, PS Sullivan, RM Novak, AC Moorman, TC Tong, SD Holmberg, JT Brooks. Incidence of cancers among HIV-infected persons in the United States, 1992-2003, *Ann Intern Med.* May 20;148(10):728-36. 2008
55. A Lavie, Y Su, M Ghassemi, RM Novak, M Caffrey, N Sekulic, C Monnerjahn, M Konrad and JL Cook. Restoration of the Antiviral Activity of AZT Against AZT-Resistant HIV by Delivery of Engineered Thymidylate Kinase to T cells. *J. General Virology*, 89(pt 7):1672-9. 2008.
56. J. Koirala, A Adamski, L. Koch, D Steuber, M El-Azizi, NM. Khardori, M Ghassemi, and RM Novak. Interferon gamma receptors in HIV-1 infection. *Aids Res. Hum. Retroviruses* 2008. Aug;24(8):1097-102.
57. M van den Berg-Wolf, K Huppler Hullsiek, G Peng, MJ Kozal, RM Novak, L Chen, LR Crane, and RD MacArthur for the CPCRA 058 Study Team, the Terry Bein Community Programs for Clinical Research on AIDS (CPCRA). Virologic, Immunologic, Clinical, Safety, and Resistance Outcomes from a Long-term Comparison of Efavirenz-Based Versus Nevirapine-Based Antiretroviral Regimens as Initial Therapy in HIV-1 Infected Persons. *HIV Clinical Trials.* 2008 Sep-Oct;9(5):324-36.
58. B. Simen, JF Simons, K Huppler-Hullsiek, RM Novak, RD MacArthur, JD Baxter, C Huang, C Lubeski, GS Trenchalk, MS Braverman, B Desany, JM Rothberg, M Egholm, MJ Kozal. Low Abundance Drug Resistant Variants in Chronically HIV-Infected Antiretroviral Naïve Patients Significantly Impact Treatment Outcomes. *J. Infect. Dis.* 2009 Mar 1;199 (5):693-701.
59. FJ Palella, C Armon, K Buchacz, SR Cole, JS Chmiel, RM Novak, K Wood, AC Moorman, JT Brooks and the HIV Outpatient Study (HOPS) Investigators. The Association of HIV Susceptibility Testing with Survival among HIV-Infected Patients Receiving Antiretroviral Therapy: A Cohort Study. *Ann Internal Med.* 2009 July 21;151 (2):73-84.
60. B Swanson, BE Sha, JK Keithley, L Fogg, J Nerad, RM Novak, O Adeyemi. Lipoprotein particle profiles by nuclear magnetic resonance spectroscopy in medically underserved HIV-infected persons. *Journal of Clinical Lipidology*, 2009, December, 3 (6): 379-384.
61. AB Trotter, N Bhayani, R Florsheim and RM Novak. Implementing Universal Oral HIV Screening in an Urban Emergency Department - Do Demographic Characteristics Impact Acceptance to Testing? *Clin Infect Dis.* 2010 January 15, 50:283.
62. K Buchacz, R Baker, FJ. Palella, JS Chmiel, KA Lichtenstein, RM Novak, KC Wood, JT Brooks, and the HOPS Investigators. AIDS-defining opportunistic illnesses in US patients, 1994–2007: a cohort study. *AIDS* 2010. 24:1549-1559.
63. DR Boulware, K Huppler Hullsiek, CE. Puroton, A Rupert, JV Baker, MA French, PR Bohjanen, RM Novak, JD Neaton and I Sereti for the INSIGHT Study Group. Higher Levels of CRP, D-dimer, IL-6 and Hyaluronic acid before Initiation of Antiretroviral Therapy (ART) are associated with Increased Risk of AIDS or Death. *J Infect Dis.* 2011 Jun;203(11):1637-1646.

64. B Swanson, JK Keithley, BE Sha, L Fogg, J Nerad, RM Novak, O Adeyemi, GT Spear. Policosanol for the management of HIV-related dyslipidemia in a medically underserved population: a randomized, controlled clinical trial. *Alternative Therapies* 2011. 17:30-35.
65. DL Pitrak, R Estes, RM Novak, M Linares-Diaz, JM Tschampa. Beneficial Effects of a Switch to a Lopinavir/ritonavir-Containing Regimen for Patients with Partial or No Immune Reconstitution with Highly Active Antiretroviral Therapy (HAART) Despite Complete Viral Suppression. *AIDS Res Hum Retroviruses*. 2011. 27:1-9.
66. FJ Palella; RK Baker, K Buchacz, JS Chmiel, EM Tedaldi, RM Novak, MD Durham, JT Brooks and the HOPS Investigators. Increased Mortality among Publicly Insured Participants in the HIV Outpatient Study (HOPS) Despite HAART Treatment. *AIDS* 2011. 25(15): 1865-76.
67. K. Buchacz, Douglas J. Ward, Rose K. Baker, Frank Palella, Joan Sander Chmiel, Benjamin Young, Bienvenido G. Yangco, RM. Novak and J. Brooks. Trends in Decline of Antiretroviral Resistance among ARV-experienced Patients in the HIV Outpatient Study (HOPS): 1999-2008. *AIDS Res Treat*. 2012;2012:230290.
68. Novak RM¹, Richardson JT², Buchacz K³, Chmiel JS⁴, Durham MD³, Palella FJ⁴, Wendrow A¹, Wood K², Young B^{5,6}, Brooks JT³ and the HOPS Investigators⁷ Immune Reconstitution Inflammatory Syndrome (IRIS) in the HIV Outpatient Study (HOPS): Incidence and Implications for Mortality. *AIDS* 2012; 6: 721 - 730.
69. Metch B, Frank I, Novak R, Swann E, Metzger D, Morgan C, Lucy D, Dunbar D, Graham P, Madenwald T, Escamilia G, Koblin B. Recruitment of Urban US Women at Risk for HIV Infection and Willingness to Participate in Future HIV Vaccine Trials. *AIDS Behav*. 2012 Oct 23.
70. GE Martin, GE, M Gouillou, AC Hearps, TA Angelovich, AC Cheng AC, F Lynch F, WJ Cheng G Paukovics, CS Palmer, RM Novak, A Jaworowski, AL Landay and SM Crowe. Age-associated changes in monocyte and innate immune activation markers occur more rapidly in HIV infected women. *PLOS One*. 2013; 8(1):e55279
71. MJ McElrath, K Smythe, J Randolph-Habecker, KR Melton, TA Goodpaster, S Hughes, M Mack, A Sato, G Diaz, G Steinbach, R Novak, M Curlin, J Lord, J Maenza, A Duerr, N Frahm, and F Hladik. CCR5⁺ macrophages are greatly enriched in human rectum compared to colon. *J AIDS*, IN PRESS.
72. HM Makinde, R Zariffard, P Mirmonsef, R Novak, O Jarrett, AL Landay, GT Spear. IL-22 is Induced in the Lower Genital Tract During *Trichomonas Vaginalis* Infection. *Am. J. Reprod. Immunol.*, IN PRESS
73. BA Koblin, B Metch, RM Novak, C Morgan, D Lucy, D Dunbar, P Graham, E Swann, T Madenwald, G Escamilia, I Frank, and the HVTN 906 study team. Feasibility of identifying a cohort of US women at high risk for HIV infection for HIV vaccine efficacy trials: Longitudinal results of HVTN 906. *J AIDS*, 2013 Feb 26.
74. RM Novak, B Metch, S Buchbinder, R Cabello, Y Donastorg, J-P Figoroa, H Abdul-Jauwad, P Joseph, E Koenig, D Metzger, M Sobieszycz, M Tyndall, C Zorilla. Risk Behavior among Women enrolled in a Randomized Controlled Efficacy Trial of an Adenoviral Vector Vaccine to Prevent HIV Acquisition: the Step Study. *AIDS*, IN PRESS

MONOGRAPHS AND BOOK CHAPTERS:

1. Clinical Management of the HIV-Infected Adult: A Manual for Mid-Level Clinicians. S. Thompson, R. Novak and K. Pursell, Eds. Emory AIDS Training Network, MATEC and DHHS, 1993, revised 1994.
2. C. Yang, S. Cai, T. Holzer, R. Novak and C. Pidgeon. "Introduction to the Human Immunodeficiency Virus" in Tutorials for Biomedical Scientists, Ed. C. Pidgeon. VCH Publishers, New York, NY , 1996.
3. C. Yang, T. Holzer, R. Novak and C. Pidgeon. "Measurements of HIV Viral Load by Polymerase Chain Reaction (PCR). in Tutorials for Biomedical Scientists, Ed. C. Pidgeon. VCH Publishers, New York, NY 1996.

BOOK REVIEWS and REVIEW ARTICLES:

1. R.M. Novak. Something for Everybody: AIDS Testing, (2nd edn). Trends in Microbiol., 3:448-9.1995
2. R.M. Novak. Human Immunodeficiency Virus: Biology, Immunology and Therapy. Perspectives in Biology and Medicine, 47(2):305-7, 2004
3. R.D. MacArthur and R.M. Novak. Maraviroc: The First of a New Class of Antiretroviral Agents. Clin Infect Dis. July 15;47(2):236-41. 2008.
4. G. Reid and R.M. Novak (2011). HIV-1 Treatment-Experienced Patients: Treatment Options and Management, Recent Translational Research in HIV/AIDS, Yi-Wei Tang (Ed.), ISBN: 978-953-307-719-2, InTech. 2011.
5. F.G. Lynch, A. Styczynski, R.M. Novak. A History of Microbicides and Their Current Development Pipeline. Drugs of the Future, 36(12): 909-918. 2011.

INVITED LECTURES:

Conference Moderator, Gram Negative Resistance Forum: A National Nosocomial Resistance Surveillance Group Program. Chicago, IL, January, 1991
 Michael Reese Hospital, Chicago, IL, September, 1991: Update on HIV Disease
 Chicago Medical Society 47th Midwest Clinical Conference, March, 1991: The Retroviral Diseases
 Osler Institute Review of Internal Medicine, Rosemont, IL, December, 1991: Review of HIV Disease. Clinical Aspects
 St. Francis Hospital, Evanston, IL, August, 1992: Clinical Management of HIV Disease
 Lutheran General Hospital, Park Ridge, IL, February, 1994: Clinical Management of HIV Disease
 Chicago Medical Society 50th Midwest Clinical Conference, March, 1994: Prophylaxis of AIDS-Related Opportunistic Infections: An Update.
 Academy of Family Physicians, Cabrini Hospital, Chicago, IL, February, 1995: Management of HIV Disease
 Westlake Hospital Grand Rounds, Cicero, IL, February, 1995: Clinical management of HIV disease
 Academy of Family Physicians, Naperville, IL, March, 1995: New Problems in Infectious Diseases
 D4T and 3TC: The 3TC Expanded Access Experience. Bristol-Myers AIDS Investigator's Meeting, February, 1996, San Diego, CA.
 Protease Inhibitors. Twins Cities Infectious Diseases Group, Minneapolis, MN, April, 1996.
 Update from the XI Int'l Conference on AIDS. AIDS Research Alliance of Chicago, Chicago, IL, August, 1996.
 HIV Update: St. Vincent's Hospital Grand Rounds, Toledo, Ohio, November, 1996
 Antiviral Treatment Strategies: Henry Ford Hospital ID. Conference, Detroit, MI, December, 1996.
 Hepatitis Overview: Kishwaukee Community Hospital, DeKalb, IL, January, 1997
 Update on HIV: Hampton VA Hospital, Hampton VA, March, 1997
 Management of HIV Drug Resistance: Phone Conference, Milwaukee, Wisconsin, October, 1999
 Update in HIV Management. Christ Hospital, April, 2000
 Effect of Change from TID to BID Nelfinavir (NFV) on Viral Load, CD4 Count and Adherence. XIII Int'l AIDS Conference, Durban South Africa, July, 2000.
 Durban Update: Chicago Health Outreach, August, 2000
 Durban Update: Illinois Masonic, August, 2000
 Antiretroviral Drug Resistance: Clinical Management of HIV and STDS, Springfield, IL, September, 2000
 Adherence to Antiretroviral therapy: National Conference on Correctional Medicine, St. Louis, MO, October, 2000.
 Update on HIV Vaccine Research. At HIV Spring Update, Miami, FL, March, 2001
 Retrospective Review of Kaletra/Delavirdine for Salvage Therapy: Rescriptor Advisory Meeting, Sonoma, CA, August, 2001

Recruitment and Retention of Women at Heterosexual Risk for HIV infection: HIV Vaccine Trials Network Quarterly Group Meeting, Seattle, WA, October, 2001
Management of HIV, 2001. Seattle, WA, October, 2001.
HIV Treatment Error Reduction Using a Genotype Database. HRSA and AHRQ Consultative Meeting on the Use of Technology in HIV Care, Rockville, MD, November, 2001.
Management of HIV, Detroit, MI, January, 2002
HIV Vaccine Update. 7th Annual Current Issues in HIV Pharmacotherapy, June 27, 2002, Oak Brook, IL.
Prevalence of Primary HIV Resistance in Treatment Naïve Patients in CPCRA 058: FIRST Trial: CPCRA Group Meeting, Washington, D.C., November, 2003.
Prevalence of Primary HIV Resistance in Treatment Naïve Patients in CPCRA 058: FIRST Trial: NIAID Grand Rounds, April, 2005.
Keynote Speaker: Antivirals Update, 2005 MATEC Fall AIDS Meeting, Detroit, MI, November 15, 2005
Medical Grand Rounds: HIV Update, 2006. Southern Illinois University Medical School, Springfield, IL, March, 2006
Pediatrics/Gyne Grand Rounds: HIV Vaccine Update. Mount Sinai Hospital, Chicago, IL. April, 2008
Ob/Gyne Grand Rounds: HIV Vaccine Update. Stroger Cook County Hospital, August, 2008.
Update in Internal Medicine Course: HIV Update. State College, Pennsylvania, September, 2010.
Immunization Update. Vista Medical Center/Victory Memorial Hospital, Waukegan, IL, March, 2011.
HIV Vaccines. 20th Annual HIV/STD Conference, Springfield, IL. September, 2011